TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: VAS (Visual Analogic Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sit and Reach flexibility test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Runtastic Performance Pedometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combination of cardiac death, non-fatal myocardial infarction, unstable angina pectoris, and revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Acute grade 3+ gastrointestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients maintaining off-therapy clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and reactogenicity of the candidate vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Shoulder Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Percentage of Participants with Treatment Resistant Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence Percentage of Participants with Treatment Resistant Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of an episode of Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Who Met All Five Criteria for Subject Performance Composite (SPC) Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global distress score (GDS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Positive skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gene expression in urothelial tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Protein expression in urothelial tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lead dislodgement
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of intraoperative microembolic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of S100B serum protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of serum interleukins and microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Albumincorrected Serum Calcium From Baseline to End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in Hepcidin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Assessment With Cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteolysis frequency change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteolysis size change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form (36) Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Trough Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photonumeric Cellulite Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to loss of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean indexed cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportions of successful implementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportions of clinics agreeing to participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Monocytes surface bound IgE quantities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Human plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCL+ in the macular area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retinal thickness in all macular regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of participants who completed the week 4 follow up assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants who report intervention acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in mean readiness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mean self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of participants who fill antimicrobial prescription early
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes on Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of digital ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Harvested numbers of lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients experiencing improvement of the target nail
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose tolerance (AUCgluc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total analgesic use after surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Change From Baseline in Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of planned and unplanned admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of tumors with microsatellite instability and/or somatic POLE mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hernia recurrence requiring surgical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline on the Self-Injurious Thoughts and Behaviors Interview-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of colony forming units (CFU) in bacterial culture of conjunctival swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antibody Titer (Serum Anti-Aβ1-42 Free IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cardiorespiratory reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of new-onset myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of axial length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Socioeconomic determinants
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Ratio of the AUC0-∞ of CO-1.01 formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset time of improvement effect of glabellar lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skeletal maturity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: SCFE radiographic characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in Total International Prostate Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Erectile Function Domain of the International Index of Erectile Function (IIEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor-specific Cytotoxic T-cell Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Field quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of functional scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of subjects reporting an adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: HBV DNA decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hepatitis B surface antigen decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Systemic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Social Support Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change of Chinese Health Questionnaire-12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Brief Psychiatric Rating Scale-18
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Global Assessment of Function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Chinese version of the Social Functioning Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Pad-weight measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With Acute Procedural Success of Re-ablation Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Documented Atrial Arrhythmias Prior to Re-ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Hospital Days for Re-ablation Procedure From Admission to Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of hematoma or seroma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Confirmation of ETT depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hospital-free days at day 90
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Postoperative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of User-related Battery Depletion Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Contraceptive Method Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: current asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite working memory z score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective symptomatic outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HPV-16 and HPV-18 antibody titers (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to induction and consolidation regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to response (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhaled dose of radioaerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC (0-t) of fruquintinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-inf) of fruquintinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with post-injection/infusion adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with AEs, discontinuations due to AEs, and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with clinically significant abnormal safety laboratory findings
Endpoint domain: Adverse events/effects
Primary endpoint: Load magnitude and duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA Expression Levels in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mRNA Expression Levels in Skin biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in level of objectively measured physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in defecation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With a Decrease in Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activity of SQ109 against H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in cross sectional area of rectus femoris (cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle layer thickness of rectus femoris (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in diaphragmatic excursion (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Absolute Disc Glycosylation Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical quality of endocytoscopic images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of abnormal clonal proliferation (ACP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polyclonal engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulation Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Grade 2 or higher adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Core Temperature Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 21 Day Organ Support Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in burden of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Androgen Receptor mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bioimpedance Percentage Difference Healthy/Operated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Limb Volume Percentage Difference Operated/Healthy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) ypT0N0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: TRG (Tumor Regression Grade)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Time With a Platelet Response During the First 6 Months of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Who Developed Collagen After Exposure to Romiplostim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Increased Modified Bauermeister Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Developed Bone Marrow Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of anticipated hemodynamic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ACR20/50/70 Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance as measured by Stroop Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance as measured by Children's Color Trails Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance as measured by Verbal Fluency Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: American Shoulder and Elbow score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Surgical operability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: D-Dimer Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: numbers of liver transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: numbers of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serial dapivirine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported genital symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction of the patient and the surgeon
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary tract infection (UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration between induction and beginning of active phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of standard chemotherapy dose delivered
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of planned chemotherapy delivered
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Mothers' Permissiveness for Daughters to Indoor Tan
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Cerebral Glucose Uptake Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Days Substance Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Control of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reductions in stimulated salivary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hematological complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Respiratory Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bioelectrical Impedance Analysis as a clinical assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (CR, CRi, or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from abuser to non-abuser
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Terminal elimination half life of ABBV-085
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of ABBV-085
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) from time zero to the last measurable concentration AUC(0-t) of ABBV-085
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Heart Rate at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All Diagnoses Occurring After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time to healing of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum change in viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pulmonary artery regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diuresis and natriuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With NIV Failure
Endpoint domain: Adverse events/effects
Primary endpoint: EVA score Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of R0 resections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in Viral Kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes